Sustained remission achieved with ATRA and chemotherapy in second relapse of acute promyelocytic leukemia in Down syndrome

Journal of Pediatric Hematology/Oncology

Volumn 31, Issue 8, 2009, Pages 539-540

  Ghosh, Indranil ^a   Kumar, Lalit ^a   Seth, Rachna ^b   Thavraj, Vasantha ^b  

^a INSTITUTE ROTARY CANCER HOSPITAL   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Acute promyelocytic leukemia; All trans retinoic acid; Down syndrome

Indexed keywords

ARSENIC TRIOXIDE; DAUNORUBICIN; MERCAPTOPURINE; METHOTREXATE; RETINOIC ACID; ANTINEOPLASTIC AGENT;

ARTICLE; BLOOD CELL COUNT; BLOOD SMEAR; BONE MARROW BIOPSY; CANCER REGRESSION; CANCER RELAPSE; CASE REPORT; CHILD; DOWN SYNDROME; ECHOCARDIOGRAPHY; FEVER; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROINTESTINAL HEMORRHAGE; HEPATOMEGALY; HUMAN; KARYOTYPE; MENINGITIS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; SEPSIS; RECURRENT DISEASE; REMISSION; REVIEW;

ANTINEOPLASTIC AGENTS; CHILD, PRESCHOOL; DOWN SYNDROME; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; RECURRENCE; REMISSION INDUCTION; TRETINOIN;

EID: 68849112429     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3181979494     Document Type: Article

References (13)

1. Creutzig U, Ritter J, Vormoor J, et al. Myelodysplasia and acute myelogenous leukemia in Down's syndrome. A report of 40 children of the AML-BFM study group. Leukemia. 1996;10:1677-1686.
2. Hasle H, Niemeyer CM, Chessells JM, et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia. 2003;17:277-282. (Pubitemid 36266902)
3. Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet. 2000;355:165-169. (Pubitemid 30068214)
4. Zipursky A, Peeters M, Poon A. Megakaryoblastic leukemia and Down's syndrome: a review. Pediatr Hematol Oncol. 1987;4:211-230.
5. Ravindranath Y, Abella E, Krischer JP, et al. Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498. Blood. 1992;80:2210-2214.
6. Rao A, Hills RK, Stiller C, et al. Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials. Br J Haematol. 2006;132:576-583. (Pubitemid 43381590)
7. Lange BJ, Kobrinsky N, Barnard DR, et al. Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group Studies 2861 and 2891. Blood. 1998;91:608-615. (Pubitemid 28053385)
8. Jain D, Singh T, Arora P. Down syndrome with microgranular variant of acute promyelocytic leukemia in a child: a case report. J Med Case Reports. 2007;1:147. (Pubitemid 351837214)
9. Kurkjian C, Patel S, Kamble R, et al. Acute promyelocytic leukemia and constitutional trisomy 21. Cancer Genet Cytogenet. 2006;165:176-179. (Pubitemid 43343513)
10. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. Blood. 1998;92:2322-2333. (Pubitemid 28452973)
11. Lie SO, Jonmundsson G, Mellander L, et al. Population-based study of 272 children with acute myeloid leukaemia treated on two consecutive protocols with different intensity: best outcome in girls, infants, and children with Down's syndrome. Nordic Society of Paediatric Haematology and Oncology (NOPHO). Br J Haematol. 1996;94:82-88. (Pubitemid 26232544)
12. Creutzig U, Zimmermann M, Reinhardt D, et al. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J Clin Oncol. 2004;22:4384-4393. (Pubitemid 41185159)
13. Taub JW, Ge Y. Down syndrome, drug metabolism and chromosome 21. Pediatr Blood Cancer. 2005;44:33-39. (Pubitemid 39602563)